This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Mrózek K, Heerema NA, Bloomfield CD . Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115–136.
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010; 10: 401.
Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, Knudson RA et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia [letter]. Leukemia 2010; 24: 2120–2122.
Alpermann T, Haferlach C, Eder C, Kohlmann A, Kern W, Haferlach T et al. Sole trisomy 8 in AML: concomitant molecular markers, stability of genetic patterns and impact on outcome. Blood 2012; 120, (abstract 2503).
Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001; 98: 1124–1129.
Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T . Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. Genes Chromosomes Cancer 2006; 45: 1164–1168.
Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183–3189.
Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56: 1418–1425.
Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S . Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308–1316.
Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 5660–5669.
Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348–2355.
Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Tanner SM, Guimond M et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA 2004; 101: 3915–3920.
Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305: 59–67.
Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107: 6334–6339.
García-Ortí L, Cristóbal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ et al. Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia. PLoS One 2012; 7: e47717.
Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26: 4148–4157.
The Cancer and Leukemia Group B (CALGB) institutions, principal investigators and cytogeneticists participating in this study are provided in the Supplementary Information. The research was supported in part by National Cancer Institute, Bethesda, MD grants CA101140, CA140158, CA114725, CA129657, CA16058, CA77658, The Coleman Leukemia Research Foundation, the Deutsche Krebshilfe—Dr Mildred Scheel Foundation (to HB) and the Research Committee of the University Freiburg, Germany (to HB), the Pelotonia Fellowship Program (to A-KE), and the Conquer Cancer Foundation (to JHM). The research for CALGB 8461, 20202 and 9665 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M Bertagnolli, Chair) and to the Alliance Statistics and Data Center (Daniel J Sargent, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. We thank Donna Bucci and the CALGB Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services, Colin G Edwards, PhD, Lisa J Sterling and Christine Finks for data management, and Dean Margeson and Kelsi B Holland for assistance in the statistical analyses. Moreover, we thank Stephan M Tanner, PhD and Albert de la Chapelle, MD, PhD for scientific discussions.
The authors declare no conflict of interest.
HB, K Maharry, K Mrózek, SV, MDR, GM and CDB contributed to the design and analysis of this study and the writing of this manuscript, and all authors agreed on the final version; HB, A-KE, KHM, SS, SPW, JHM, Y-ZW and PP carried out laboratory-based research; K Maharry, SV, MDR, JK and DN performed statistical analyses; and BLP, THC, MW, JEK, AJC, MRB, MAC, RMS, GM and CDB were involved directly or indirectly in the care of patients and/or sample procurement.
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
Becker, H., Maharry, K., Mrózek, K. et al. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia 28, 1754–1758 (2014). https://doi.org/10.1038/leu.2014.114
This article is cited by
Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8
Annals of Hematology (2017)
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors